# Understanding real chemistry and life sciences commercialization

**Created:** 12/20/2025 11:47:34  
**Updated:** 12/20/2025 12:07:14  
**Exported:** 12/20/2025 12:37:53  
**Link:** [https://claude.ai/chat/3217ea6a-8999-4258-8da9-556b017311d8](https://claude.ai/chat/3217ea6a-8999-4258-8da9-556b017311d8)  

## Response:
12/20/2025, 12:01:43 PM

````plaintext
Thought process: Investigated Real Chemistry, Swoop spinout, and life sciences marketing landscape.

The user is asking about two things:
1. "Real Chemistry" - this appears to be a company, and they mention "Matt Holt carved out" something called "Swoop" - this sounds like a company or business unit that was spun out
2. The broader life sciences commercial and marketing space

As a healthcare VC, they want to understand:
- The technical/strategic insights
- The "so what" - what this means for investment, market dynamics, etc.

Let me search for information about Real Chemistry and Swoop/Matt Holt to get current details.
````

I'll dig into Real Chemistry, the Swoop carve-out, and the broader life sciences commercial/marketing landscape for you. Let me search for the latest.

````plaintext
Web Search: Real Chemistry life sciences marketing company overview
````

> **Real Chemistry** [realchemistry.com](https://www.realchemistry.com/)
>
> **Real Chemistry Company Overview, Contact Details & Competitors | LeadIQ** [leadiq.com](https://leadiq.com/c/real-chemistry/604fea3edc43be7f73074f5b)
>
> **Real Chemistry - Wikipedia** [wikipedia.org](https://en.wikipedia.org/wiki/Real_Chemistry)
>
> **Real Chemistry | LinkedIn** [linkedin.com](https://www.linkedin.com/company/therealchemistry)
>
> **Real Chemistry grows in med comms with Avant buy | pharmaphorum** [pharmaphorum.com](https://pharmaphorum.com/news/real-chemistry-grows-med-comms-avant-buy)
>
> **Real Chemistry (The WeissComm Group Ltd. d/b/a ). (3/10/21). "Press Release: W2O Becomes Real Chemistry, a Global Health Innovation Company Designed to Improve Outcomes Across Today’s Healthcare Ecosystem". San Francisco, CA. - [LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal** [life-sciences-usa.com](https://www.life-sciences-usa.com/news/w2o-the-weisscomm-group-ltd-real-chemistry-2021-2001-120354.html)
>
> **W2O rebrands as Real Chemistry, rolling up acquisitions, hires and business growth under new moniker | Fierce Pharma** [fiercepharma.com](https://www.fiercepharma.com/marketing/w2o-rebrands-as-real-chemistry-rolling-up-acquisitions-hires-and-business-growth-under)
>
> **Real Chemistry | O'Dwyer's PR Firms Directory** [odwyerpr.com](https://www.odwyerpr.com/pr_firms_database/1191/real-chemistry.html)
>
> **W20 rebrands as Real Chemistry | pharmaphorum** [pharmaphorum.com](https://pharmaphorum.com/news/w20-rebrands-as-real-chemistry)
>
> **W2O rebrands as Real Chemistry - MM+M - Medical Marketing and Media** [mmm-online.com](https://www.mmm-online.com/home/channel/w2o-rebrands-as-real-chemistry/)
>
````plaintext
Thought process

Good, I have foundational info on Real Chemistry. Now let me search specifically for the Swoop carve-out and Matt Holt to understand that specific piece.
````

````plaintext
Web Search: Swoop Matt Holt Real Chemistry carve out spin out
````

> **PR News | Swoop Splits from Real Chemistry - Fri., Sep. 6, 2024** [odwyerpr.com](https://www.odwyerpr.com/story/public/21795/2024-09-06/swoop-splits-from-real-chemistry.html)
>
> **Swoop spins off from Real Chemistry | PR Week** [prweek.com](https://www.prweek.com/article/1887438/swoop-spins-off-real-chemistry)
>
> **Swoop spins off from Real Chemistry - MM+M - Medical Marketing and Media** [mmm-online.com](https://www.mmm-online.com/home/channel/agencies/swoop-spins-off-from-real-chemistry/)
>
> **Swoop spins off from Real Chemistry | Campaign US** [campaignlive.com](https://www.campaignlive.com/article/swoop-spins-off-real-chemistry/1887531)
>
> **New Mountain Capital Establishes Swoop as Independent Company to Power the Omnichannel Revolution in Healthcare Engagement** [businesswire.com](https://www.businesswire.com/news/home/20240904145950/en/New-Mountain-Capital-Establishes-Swoop-as-Independent-Company-to-Power-the-Omnichannel-Revolution-in-Healthcare-Engagement)
>
> **Swoop nabs MyHealthTeam after Real Chemistry spinoff, poised for more deals** [mmm-online.com](https://www.mmm-online.com/news/swoop-nabs-myhealthteam-poised-for-more-deals/)
>
> **New Mountain Capital Establishes Swoop as Independent Company to Power the Omnichannel Revolution in Healthcare Engagement | Business Wire** [businesswire.com](https://www.businesswire.com/news/home/20240904145950/en)
>
> **Swoop nabs MyHealthTeam after Real Chemistry spinoff, poised for more deals | PR Week** [prweek.com](https://www.prweek.com/article/1901452/swoop-nabs-myhealthteam-real-chemistry-spinoff-poised-deals)
>
> **New Mountain Capital Establishes Swoop as Independent Company to Power the Omnichannel Revolution in Healthcare Engagement - Swoop** [swoop.com](https://swoop.com/blog/new-mountain-capital-establishes-swoop-as-independent-company-to-power-the-omnichannel-revolution-in-healthcare-engagement/)
>
> **Shankar Narayanan, Real Chemistry** [investmentreports.co](https://www.investmentreports.co/interview/shankar-narayanan-1466)
>
````plaintext
Thought process: Synthesizing Swoop insights and mapping competitive life sciences landscape.

Now I have good information on the Swoop carve-out and Matt Holt's role (he's Managing Director and President of PE at New Mountain Capital). Let me now search for more context on the life sciences commercial and marketing landscape and competitors to get a fuller picture.
````

````plaintext
Web Search: life sciences pharma marketing agencies competitive landscape 2024 2025
````

> **6 Innovative Pharma Marketing Agencies Making Waves in 2025 - On the Pulse: Pharma Marketing and Life Sciences Blog | Pulse Health** [pulsehealth.tech](https://blog.pulsehealth.tech/6-innovative-pharma-marketing-agencies-in-2025/)
>
> **The 9 Best Life Sciences Marketing Agencies in 2025** [thedigitalelevator.com](https://thedigitalelevator.com/blog/life-sciences-marketing-agencies/)
>
> **The 15 Best Pharma Marketing Agencies in 2025** [supremeopti.com](https://www.supremeopti.com/best-pharma-marketing-agencies/)
>
> **The 7 Best Pharmaceutical Marketing Agencies in 2025** [thedigitalelevator.com](https://thedigitalelevator.com/blog/pharmaceutical-marketing-agencies/)
>
> **The 10 Best Life Science Marketing Agencies in 2025** [biostratamarketing.com](https://www.biostratamarketing.com/the-best-life-science-marketing-agencies)
>
> **8 Key Life Sciences Marketing Trends for 2024 - Altitude Marketing** [altitudemarketing.com](https://altitudemarketing.com/blog/life-sciences-marketing-trends-2024/)
>
> **Life Sciences Marketing Trends In 2024 | Sciencia Consulting** [scienciaconsulting.com](https://scienciaconsulting.com/life-sciences-marketing-trends-2024/)
>
> **The Ultimate Guide to Life Science Marketing - Tips for 2025 - MarketBeam** [marketbeam.io](https://marketbeam.io/comprehensive-guide-to-life-science-marketing/)
>
> **Top Pharmaceutical Marketing Agencies to Work With - November 2025 | G & Co.** [g-co.agency](https://www.g-co.agency/insights/top-pharmaceutical-marketing-agencies-to-work-with)
>
> **Life Sciences Under the Microscope: Key 2024 Takeaways and What’s Ahead for 2025 | Insights | Ropes & Gray LLP** [ropesgray.com](https://www.ropesgray.com/en/insights/alerts/2025/02/key-takeaways-from-the-life-sciences-industry-in-2024-and-whats-next)
>
````plaintext
Thought process

Let me get more specific information on the key players and competitive dynamics in the life sciences marketing space, and understand what Swoop actually does technically.
````

````plaintext
Web Search: Swoop pharma healthcare marketing technology platform capabilities
````

> **Homepage - Swoop** [swoop.com](https://swoop.com/)
>
> **Swoop Unveils Groundbreaking AI-Driven Innovations at Digital Pharma East, Reimagining HCP Marketing** [businesswire.com](https://www.businesswire.com/news/home/20240909542329/en/Swoop-Unveils-Groundbreaking-AI-Driven-Innovations-at-Digital-Pharma-East-Reimagining-HCP-Marketing)
>
> **Swoop | LinkedIn** [linkedin.com](https://www.linkedin.com/company/swoop)
>
> **Swoop Launches Proprietary GenAI Platform with Custom Privacy-Safe AI Assistants to Transform Omnichannel Marketing for Pharma Brands - Swoop** [swoop.com](https://swoop.com/blog/swoop-launches-proprietary-genai-platform-with-custom-privacy-safe-ai-assistants-to-transform-omnichannel-marketing-for-pharma-brands/)
>
> **Swoop Launches Predictive AI Targeting, the Next Generation of Healthcare Marketing** [businesswire.com](https://www.businesswire.com/news/home/20240104118397/en/Swoop-Launches-Predictive-AI-Targeting-the-Next-Generation-of-Healthcare-Marketing)
>
> **Swoop to Showcase Award Winning AI-Driven Innovations for Healthcare Marketers at CES** [businesswire.com](https://www.businesswire.com/news/home/20250102880001/en/Swoop-to-Showcase-Award-Winning-AI-Driven-Innovations-for-Healthcare-Marketers-at-CES)
>
> **Swoop Launches Proprietary GenAI Platform with Custom Privacy-Safe AI Assistants to Transform Omnichannel Marketing for Pharma Brands** [businesswire.com](https://www.businesswire.com/news/home/20241014039992/en/Swoop-Launches-Proprietary-GenAI-Platform-with-Custom-Privacy-Safe-AI-Assistants-to-Transform-Omnichannel-Marketing-for-Pharma-Brands)
>
> **Swoop Unveils Groundbreaking AI-Driven Innovations at Digital Pharma East, Reimagining HCP Marketing - Swoop** [swoop.com](https://swoop.com/blog/swoop-unveils-groundbreaking-ai-driven-innovations-at-digital-pharma-east-reimagining-hcp-marketing/)
>
> **Dynamic Insights: How Swoop Piper Accelerates Innovation in Pharma Marketing - Swoop** [swoop.com](https://swoop.com/blog/dynamic-insights-how-swoop-piper-accelerates-innovation-in-pharma-marketing/)
>
> **Swoop Expands Patient-Centric Engagement with Acquisition of MyHealthTeam, a Leading Opted-In Patient Community in the U.S. | MyHealthTeam** [myhealthteam.com](https://myhealthteam.com/recent-news/swoop-expands-patient-centric-engagement-with-acquisition-of-myhealthteam-a-leading-opted-in-patient-community-in-the-u-s/)
>
````plaintext
Thought process: Pivoted toward mapping competitive landscape within life sciences sector.

This is great information on Swoop. Now let me search for competitive landscape - who else is in this space competing with Swoop and Real Chemistry.
````

````plaintext
Web Search: pharma HCP DTC marketing ad tech Veeva Definitive Healthcare PulsePoint IQVIA competitors
````

> **Best DSPs for Pharma Advertising | Top Platforms for Healthcare Marketing — Traffic Engine** [trafficengine.io](https://www.trafficengine.io/blog/best-dsps-for-pharma-advertising)
>
> **Veeva Crossix and Big Data: Transforming Healthcare Marketing Analytics | IntuitionLabs** [intuitionlabs.ai](https://intuitionlabs.ai/articles/veeva-crossix-big-data-healthcare-marketing-analytics-pharma)
>
> **IQVIA CRM vs. Veeva CRM in Pharma: An In-Depth Comparison | IntuitionLabs** [intuitionlabs.ai](https://intuitionlabs.ai/articles/iqvia-crm-vs-veeva-crm)
>
> **FEDERAL TRADE COMMISSION v. IQVIA HOLDINGS INC PROPEL MEDIA INC (2024) | FindLaw** [findlaw.com](https://caselaw.findlaw.com/court/us-dis-crt-sd-new-yor/115690555.html)
>
> **Rethinking Healthcare Professional (HCP) Engagement in the Face of Potential Direct-to-Consumer (DTC) Advertising Restrictions - Tealium** [tealium.com](https://tealium.com/blog/customer-data-platform/rethinking-healthcare-professional-hcp-engagement-in-the-face-of-potential-direct-to-consumer-dtc-advertising-restrictions/)
>
> **IQVIA VS. VEEVA: Comparing Pharma's Top Platforms | Assemble Studio - Web Development & Digital Production** [assemblestudio.com](https://www.assemblestudio.com/blog/iqvia-vs-veeva-comparing-pharmas-top-platforms)
>
> **Sourcing and Engaging Physicians for Pharma Sales in the U.S. | IntuitionLabs** [intuitionlabs.ai](https://intuitionlabs.ai/articles/sourcing-hcp-for-pharma-sales)
>
> **IQVIA vs Veeva CRM: A Life Sciences CRM Comparison (2025) | IntuitionLabs** [intuitionlabs.ai](https://intuitionlabs.ai/articles/iqvia-vs-veeva-crm-comparison)
>
> **High five: How these companies are leveraging data to engage A-list HCPs - MM+M - Medical Marketing and Media** [mmm-online.com](https://www.mmm-online.com/home/channel/features/high-five-how-these-companies-are-leveraging-data-to-engage-a-list-hcps/)
>
> **UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK** [appliedantitrust.com](https://appliedantitrust.com/14_merger_litigation/cases_ftc/iqvia2023/02_sdny/iqvia_sdny_pff_pcl_ftc2023_12_18.pdf)
>
````plaintext
Thought process

This is excellent competitive information. Now I have a good picture of the landscape. Let me do one more search to round out the picture on market size and PE activity in this space.
````

````plaintext
Web Search: life sciences marketing agencies private equity investment M&A 2024 2025
````

> **Trends and Tips for Navigating Life Sciences M&A in 2024 – Publications** [morganlewis.com](https://www.morganlewis.com/pubs/2024/05/trends-and-tips-for-navigating-life-sciences-m-a-in-2024)
>
> **Life Sciences M&A Outlook: What’s Driving Deals in 2025?** [redbock.com](https://redbock.com/news/life-sciences-m-a-outlook/)
>
> **TH Healthcare & Life Sciences: Investment Banking | M&A Advisors** [thhealthcare.com](https://thhealthcare.com/)
>
> **Life sciences: Primed for an increase | McKinsey** [mckinsey.com](https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-primed-for-an-increase)
>
> **Life Sciences Under the Microscope: Key 2024 Takeaways and What’s Ahead for 2025 | Insights | Ropes & Gray LLP** [ropesgray.com](https://www.ropesgray.com/en/insights/alerts/2025/02/key-takeaways-from-the-life-sciences-industry-in-2024-and-whats-next)
>
> **Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?** [cooleyma.com](https://cooleyma.com/2025/01/22/cooleys-2024-life-sciences-ma-year-in-review-ma-slims-down-in-2024-but-will-appetites-grow-in-2025/)
>
> **M&A Considerations Across the Evolving Life Sciences Sector: Key Takeaways – Publications** [morganlewis.com](https://www.morganlewis.com/pubs/2025/04/m-and-a-considerations-across-the-evolving-life-sciences-sector-key-takeaways)
>
> **Private capital: Life science investment trends to expect in 2024 | Insights | Ropes & Gray LLP** [ropesgray.com](https://www.ropesgray.com/en/insights/viewpoints/102ivl1/private-capital-life-science-investment-trends-to-expect-in-2024)
>
> **Healthcare & Life Sciences M&A: A Year in Review & Future 2025 Outlook | Alvarez & Marsal | Management Consulting | Professional Services** [alvarezandmarsal.com](https://www.alvarezandmarsal.com/insights/healthcare-life-sciences-ma-year-review-future-2025-outlook)
>
> **Private Equity Funding Projections for Life Sciences 2026 | BDO** [bdo.com](https://www.bdo.com/insights/industries/life-sciences/the-2026-outlook-on-private-equity-funding-in-life-sciences)
>
````plaintext
Thought process: Synthesized comprehensive insights for healthcare venture capital analysis.

Now I have comprehensive information. Let me synthesize all of this into a clear breakdown for a healthcare VC.
````

I've got a comprehensive view now. Let me synthesize this into a structured breakdown for you.

---

## Real Chemistry & Swoop: The Full Picture

### **The Core Company: Real Chemistry**

Real Chemistry is a global provider of marketing and analytics services, including public relations, to the healthcare and technology industries. Founded by Jim Weiss in 2001, it rebranded from W2O Group to Real Chemistry in March 2021 after a roll-up of 12+ acquisitions.

**Scale & Position:**
- Generates between $1-10B in revenue, employs approximately 2,500 people across 5 continents
- The second largest PR firm by revenue in O'Dwyer's rankings and the largest in the healthcare sector as of 2023
- Backed by **New Mountain Capital** since 2019

**The M&A Roll-Up Strategy (2019-2024):**
- 2020: Acquired starpower LLC (entertainment/influencer marketing)
- Jan 2021: Acquired **Swoop** and **IPM.ai** (data/analytics)
- 2022: Acquired conversationHEALTH (conversational AI)
- 2023: Acquired TI Health (predictive analytics, HCP marketing) → folded into Swoop
- 2024: Acquired Avant Healthcare (medical communications)

**Core Capability Stack:**
- **Communications/PR** (W2O heritage)
- **Advertising** (21GRAMS)
- **Medical Communications** (Avant)
- **Data/Analytics** (Swoop, IPM.ai)
- **Clinical Trial Engagement** (Hu)
- **Value-Based Care Consulting** (Discern)

---

### **The Swoop Carve-Out (Sept 2024)**

This is the move you referenced, orchestrated by **Matt Holt, Managing Director and President of Private Equity at New Mountain Capital.**

**What Happened:**
New Mountain Capital established Swoop as a standalone business after four years operating as a unit of Real Chemistry. Both businesses grew exponentially during this period.

**Why It Matters (Matt Holt's Rationale):**
"The establishment of Swoop as a standalone business focused on innovative data and technology applications represents an exciting next step in that evolution. We are thrilled with the progress to date, and look forward to continuing to support the growth of both Swoop and Real Chemistry as industry-leading platforms during this next phase."

**Key Structural Details:**
- New Mountain Capital remains the majority owner of both Real Chemistry and Swoop—structure unchanged
- The two agencies maintain a "preferred partnership arrangement"
- Real Chemistry acquired Swoop in 2021 alongside IPM.ai; TI Health was integrated under Swoop in 2023 to merge HCP services with DTC audiences

**The Strategic Logic:**
This is a classic PE "dual-platform" playbook: separate the high-growth tech/data asset (Swoop) from the services business (Real Chemistry) to:
1. Give each independent investment capacity and strategic focus
2. Create optionality for different exit paths (Swoop = tech multiple; Real Chemistry = services multiple)
3. Allow Swoop to partner with Real Chemistry *competitors* (more on that below)

---

### **Deep Dive: What Swoop Actually Does**

Swoop is a **healthcare marketing technology platform** focused on precision audience targeting and omnichannel activation.

**Core Technical Capabilities:**
Swoop's HIPAA-certified and NAI-accredited system uses AI, machine learning and evolutionary computation in conjunction with a real world data universe of over 300 million de-identified patients and 65 billion anonymized social determinants of health signals to uncover unique target audiences for activating patient populations.

**Product Suite:**
1. **Predictive AI Targeting** – Allows healthcare marketers to target patients and providers prior to diagnosis, those most likely to adopt a newly launched therapy, progress to a new line of treatment, or become non-adherent

2. **HCP Pro Suite** – Includes Swoop NPI Pro and Swoop PLD Pro, leveraging AI and privacy-safe data strategies to address complexities of omnichannel marketing to HCPs

3. **Swoop Piper GenAI Platform** – AI-powered tools that enable pharma marketers to dynamically interact with their data through custom AI Assistants (HCP Assistants, DTC Assistants, Data Analyst Assistants)

4. **Conversational AI Agents** – MLR-approved chatbots for brand websites

**Recent Acquisition (Post-Spin-Off):**
In January 2025, Swoop acquired MyHealthTeam, the largest opted-in patient community network in the U.S. with 62+ condition-specific communities. Ron Elwell (Swoop CEO) noted this is a new line of business, not synergy-driven—indicating a push into first-party patient engagement data.

**Competitive Positioning:**
Swoop has partnered with Ogilvy Health, Saatchi & Saatchi, FCBHealth, Klick Health, Digital, Evoke, Wunderman Thompson and McCann Health—these are Real Chemistry competitors. The spin-off unlocked Swoop's ability to be an arms dealer to the whole agency ecosystem.

---

## The Broader Life Sciences Commercial & Marketing Landscape

### **Market Structure: Three Tiers**

**Tier 1: Infrastructure/Platform Players (Big Data + CRM)**
- **Veeva Systems** – Dominates ~80% of global life sciences CRM market with 1,500+ customers
- **IQVIA** – OCE has ~400 customers in 130 countries; massive syndicated data (OneKey, prescription/claims databases)
- **Definitive Healthcare** – Reference data, KOL mapping
- These are the operating system layer pharma runs on

**Tier 2: AdTech/MarTech (Programmatic & Targeting)**
- The three leading healthcare-specific DSPs—DeepIntent, Lasso (owned by IQVIA), and PulsePoint—are referred to in IQVIA's internal business records as the "Big 3"
- **Swoop** – Precision audience targeting/activation
- **Veeva Crossix** – Links advertising exposures to actual health events; more than 200 pharmaceutical brands rely on Crossix services
- **Doceree** – HCP-focused programmatic

**Tier 3: Agency Holding Companies + Specialists**
- **Full-service healthcare networks:** Publicis Health, Ogilvy Health, Inizio Evoke, IPG Health
- **Independent specialists:** Real Chemistry, Klick Health, Avalere Health
- **Med Comms specialists:** Avant (now Real Chemistry), Peregrine (now Klick)

### **Key Competitive Dynamics**

**1. IQVIA vs. Veeva: The Cold War**
In 2017, Veeva filed an antitrust lawsuit against IQVIA, alleging anti-competitive practices to maintain dominance in healthcare data and analytics. The case is ongoing with a jury trial expected in February 2025.

**2. FTC Antitrust Action on IQVIA/DeepIntent**
The FTC brought action to preliminarily enjoin IQVIA's acquisition of DeepIntent, alleging the merger would substantially lessen competition in HCP programmatic advertising by combining two of the "Big 3" with Lasso. This signals regulatory scrutiny on consolidation in the HCP adtech layer.

**3. PE Roll-Ups Accelerating**
PE activity in life science dealmaking regained momentum, increasing its share from 11% of industry deal volume in 2023 to 15% in 2024. Healthcare marketing agencies are attractive targets given recurring revenue, pharma budget resilience, and fragmentation.

---

## The "So What" for a Healthcare VC

### **Thesis 1: Swoop Is Positioned as a Platform Company**
The spin-off re-rates Swoop from "agency asset" to "healthcare adtech platform." The MyHealthTeam acquisition signals a move toward owning first-party patient data—not just targeting third-party data. If they build a closed-loop ecosystem (community → targeting → activation → measurement), they become a Veeva Crossix competitor, not just an agency tool.

**Watch for:** Can Swoop maintain partnerships with Real Chemistry competitors post-spin? If FCBHealth and Ogilvy Health adopt Swoop at scale, it validates the arms-dealer strategy.

### **Thesis 2: The Agency Layer Is Commoditizing**
Real Chemistry without Swoop is essentially a services rollup—strong in med comms and PR, but less differentiated on data/tech. The question is whether they can compete against:
- **Klick Health** (independent, owns their own tech stack, just acquired Peregrine for market access)
- **Inizio Evoke** (massive scale, backed by Advent)
- **Publicis/IPG** (global holding company resources)

The strategic value of agencies increasingly comes from proprietary data assets, not creative services alone.

### **Thesis 3: The HCP Programmatic Layer Is Regulatory Risk-Exposed**
The FTC's action on IQVIA/DeepIntent suggests consolidation among the "Big 3" DSPs is capped. This is bullish for smaller players (Swoop, Doceree) who can grow organically or via smaller tuck-ins without tripping antitrust thresholds.

### **Thesis 4: Veeva's Vertical Integration Creates Friction Opportunities**
Veeva is well-known for its CRM used by pharma sales reps and its content management for medical communications. Having Crossix within Veeva potentially offers an advantage that competitors can't easily match: a fully integrated pharma commercial platform combining sales, marketing, and data.

The risk for Veeva: anticompetitive behavior claims (see the IQVIA lawsuit). The opportunity for startups: build point solutions that integrate cleanly with Veeva but avoid vendor lock-in.

### **Thesis 5: First-Party Data Is the New Moat**
Swoop's MyHealthTeam acquisition, Veeva's Crossix, and IQVIA's claims data are all bets that **owning the patient relationship** is more defensible than licensing it. For VCs, this suggests:
- Patient engagement platforms with clean consent frameworks are acquisition targets
- Rare disease communities (high engagement, small populations) are especially valuable
- Anything that creates "opted-in" patient data is gold in a post-cookie, privacy-first world

---

### **Bottom Line**

Real Chemistry is a well-executed PE services rollup that hit natural limits—hence the Swoop spin-off to unlock tech-multiple optionality. Swoop is the higher-beta bet: if they execute on becoming the infrastructure layer for pharma omnichannel marketing (like a "Segment for healthcare"), it's a multi-billion outcome. If they stay narrow as an audience provider, it's a solid but capped business.

The broader sector is consolidating around a few key platforms (Veeva, IQVIA) with regulatory scrutiny now acting as a ceiling on Big 3 DSP consolidation. That creates space for differentiated point solutions—especially those with proprietary patient data or novel AI applications.

Want me to go deeper on any specific player, the regulatory dynamics, or comparable investment opportunities in this space?



## Response:
12/20/2025, 12:04:10 PM

````plaintext
Thought process: Investigating Solstice's exposure to Real Chemistry/Swoop dynamics.

The user is asking about a company called "Solstice" that appears to be a portfolio company (port co) of theirs. They want me to search their Google Drive for relevant materials about Solstice and understand how it's impacted by the Real Chemistry/Swoop dynamics and the broader life sciences marketing landscape.

Let me search their Google Drive for materials related to Solstice.
````

**google_drive_search**

*Request*

````javascript
{
  "api_query": "name contains 'Solstice'",
  "page_size": 10,
  "semantic_query": "Solstice portfolio company healthcare life sciences marketing"
}
````

*Response*

````plaintext
Thought process

I found Solstice materials. Let me fetch the full fundraise planning document to get more context on what Solstice does and their positioning.
````

**google_drive_fetch**

*Request*

````javascript
{
  "document_ids": [
    "1-twM-6HYJgzrTqtR3AYFp_RPkoA14MySRak-QBG_Kzo"
  ]
}
````

*Response*

````plaintext
Thought process: Synthesized Solstice context and pursued supplementary research materials.

Excellent - now I have a much clearer picture of Solstice. Let me search for more materials to get additional context on their competitive positioning and any other relevant details.
````

Let me search for more context on Solstice's competitive positioning and any recent updates.

**google_drive_search**

*Request*

````javascript
{
  "api_query": "fullText contains 'Solstice' and fullText contains 'competitive'",
  "page_size": 10,
  "semantic_query": "Solstice competitive landscape Real Chemistry agencies content"
}
````

*Response*

````plaintext
Thought process: Pivoted search strategy after initial query yielded no results.

No results for that query. Let me try a different search.
````

**google_drive_search**

*Request*

````javascript
{
  "api_query": "fullText contains 'Solstice'",
  "page_size": 15,
  "semantic_query": "Solstice investment thesis market competitors Veeva content creation"
}
````

*Response*

````plaintext
Thought process

The running meeting notes file is too large to fetch. Let me search for any other Solstice-related documents that might have competitive analysis or market positioning.
````

**google_drive_search**

*Request*

````javascript
{
  "api_query": "fullText contains 'life sciences' and fullText contains 'content'",
  "page_size": 10,
  "semantic_query": "life sciences marketing content creation AI agency Veeva MLR compliance"
}
````

*Response*

````plaintext
Thought process

No additional results. Let me try searching for Veeva-related documents or anything about the content creation market.
````

**google_drive_search**

*Request*

````javascript
{
  "api_query": "fullText contains 'Veeva'",
  "page_size": 10,
  "semantic_query": "Veeva pharma marketing content MLR compliance digital asset management"
}
````

*Response*

````plaintext
Thought process: Investigated competitive landscape to contextualize Solstice positioning.

Let me do a web search to understand the competitive landscape for AI-powered content creation in life sciences to provide better context for Solstice's positioning.
````

````plaintext
Web Search: life sciences pharma AI content creation MLR compliance Veeva Vault PromoMats startups
````

> **Veeva PromoMats | Compliant Promotional Content Management | Veeva** [veeva.com](https://www.veeva.com/products/veeva-promomats/)
>
> **Veeva AI for PromoMats | Veeva** [veeva.com](https://www.veeva.com/products/veeva-ai-for-promomats/)
>
> **Next-gen MLR Review with AI | Veeva** [veeva.com](https://www.veeva.com/resources/building-the-future-of-mlr-with-ai-fastest-path-to-approved-content/)
>
> **Veeva PromoMats: The Complete Guide for Pharma Marketers, Sales Reps, and MSLs | IntuitionLabs** [intuitionlabs.ai](https://intuitionlabs.ai/articles/veeva-promomats-promotional-materials-management-software-for-pharma-marketing)
>
> **Veeva PromoMats Implementation: A Compliance Workflow Guide | IntuitionLabs** [intuitionlabs.ai](https://intuitionlabs.ai/articles/veeva-promomats-implementation-compliance-guide)
>
> **Veeva PromoMats – Digital Asset Management | Veeva** [veeva.com](https://www.veeva.com/products/veeva-promomats/digital-asset-management/)
>
> **Speed Content Creation and Reduce MLR Bottlenecks: What’s New in Vault 19R3 | Veeva** [veeva.com](https://www.veeva.com/blog/speed-content-creation-and-reduce-mlr-bottlenecks-whats-new-in-vault-19r3/)
>
> **Vault Promomats | Veeva Systems APAC Site** [veeva.com](https://www.veeva.com/ap/products/vault-promomats/)
>
> **Copli - Funding: $100K+ | StartupSeeker** [startup-seeker.com](https://startup-seeker.com/company/copli~io)
>
> **Veeva PromoMats – Review and Approve | Veeva** [veeva.com](https://www.veeva.com/products/veeva-promomats/mlr-review/)
>
````plaintext
Thought process: Synthesized Solstice's port operations within broader market context.

Now I have a very clear picture of Solstice and how it relates to the broader landscape I described earlier. Let me synthesize this for the user.
````

Now I have the full picture. Let me break down how Solstice fits into the Real Chemistry/Swoop landscape and what the competitive dynamics mean for your portco.

---

## Solstice: Positioning Within the Landscape

Based on your fundraise doc, Solstice is a digital life sciences marketing agency that helps biopharma companies create compliant content for their drugs 100x faster and more effectively than existing content partners. They are a full-stack replacement for everything a content agency does—creating content, evaluating it for compliance, annotating and fact-checking, as well as submitting into a client's digital asset management system (usually Veeva). You can think of them as Real Chemistry but faster, more efficient, and with even better margins.

**The Core Value Prop:**
Solstice allows biopharma marketers to take control of their content and be their own agencies. They provide a platform to go from idea to compliant, production-ready content within minutes instead of months.

---

## How Real Chemistry / Swoop Dynamics Impact Solstice

### **1. Real Chemistry = Direct Competitor (and Validation)**

Solstice explicitly positions against Real Chemistry in the fundraise materials. The key framing: "Life sciences marketing is a $40B industry. Top marketing agencies like Real Chemistry rake in >$600M ARR to make marketing, medical, and market access content for their biopharma clients. They charge really high rates, as much as $50k for a 10 page slide deck."

**The Solstice Thesis on Why Agencies Are Vulnerable:**
Agencies are incredibly expensive because they hire PharmDs, PhDs, etc. to create content and have long, unnecessary processes that add overhead without impacting quality. AI makes content creation way easier and many biopharma companies are already exploring leveraging tech to make content themselves instead of through agencies.

**This is bullish for Solstice because:**
- The Swoop carve-out signals New Mountain is separating "tech" from "services"—tacit admission that pure services (Real Chemistry's remaining business) faces margin pressure
- Real Chemistry's post-spin-off business is essentially med comms + PR + creative services, which is exactly what Solstice is trying to disintermediate with software

### **2. Swoop Is NOT a Direct Competitor—They're Complementary**

Swoop focuses on **audience targeting and activation** (finding and reaching HCPs/patients). Solstice focuses on **content creation** (making the assets that get delivered). These are sequential steps in the pharma marketing funnel:

```
[Content Creation] → [Targeting/Segmentation] → [Activation/Delivery] → [Measurement]
     Solstice              Swoop                    Swoop/DSPs           Crossix
```

**Implication:** Swoop's spin-off and aggressive M&A (MyHealthTeam acquisition) doesn't threaten Solstice. If anything, Swoop's growth validates that pharma is investing heavily in tech-enabled commercialization—which creates tailwinds for Solstice.

### **3. Veeva Is Both Platform and Emerging Competitor**

Solstice integrates into Veeva Vault PromoMats (the industry-standard DAM/MLR system). But Veeva is now building its own AI capabilities:

Veeva AI for PromoMats enhances how life sciences teams review and approve content by combining human expertise with AI precision. Built natively into the Vault Platform, it utilizes two standard agents: the Quick Check Agent scans content using editorial, brand, market, channel, and compliance guidelines before MLR review, and the Content Agent provides context-aware insights into document text and images.

**The Risk/Opportunity Matrix:**

| Veeva Move | Risk to Solstice | Opportunity for Solstice |
|------------|------------------|-------------------------|
| AI Quick Check Agent | Commoditizes pre-MLR compliance checking | Solstice's *creation* is upstream—Veeva only helps *review* existing content |
| Content Agent | Could expand into content suggestions | Veeva's DNA is workflows, not creative—they're unlikely to build full content generation |
| Native integration | Makes it harder for point solutions to differentiate | Solstice already integrates to Veeva; being "Veeva-compatible" is table stakes |

**Key insight from your doc:** Marketers would like to create content themselves, but existing tools are not purpose-built for life sciences and so custom configurations and effort required is too big of a lift. Larger biopharma companies are trying to build their own in-house content factories but are struggling to get to production-ready content.

This is Solstice's moat: Veeva helps you *manage and review* content, but doesn't help you *create* it. The creation layer is what agencies (Real Chemistry, 21GRAMS, Avant) currently own—and what Solstice is attacking with AI.

---

## Competitive Landscape for Solstice

### **Direct Competitors (Content Creation Layer)**

1. **Traditional Agencies** (Real Chemistry, Klick Health, Inizio Evoke)
   - High-touch, expensive, slow
   - Solstice's explicit displacement target

2. **Emerging AI-Native Players**
   - Copli automates the MLR review process for Life Science companies by utilizing AI to detect marketing compliance issues and provide real-time, actionable solutions. As an official Veeva AI Partner, Copli integrates with Veeva Vault PromoMats.
   - Copli is more narrowly focused on MLR review automation, not content creation—less direct overlap with Solstice

3. **In-House "Content Factories"**
   - Large pharma (Sanofi, Pfizer, J&J) experimenting with internal AI-powered content teams
   - Per your doc: Larger biopharma companies are trying to build their own in-house content factories but are struggling to get to production-ready content. Building technology is not their strong suit.
   - Solstice's opportunity is to be the platform these internal teams run on

### **Adjacent Players (Not Direct Competitors)**

| Company | What They Do | Relationship to Solstice |
|---------|--------------|--------------------------|
| Swoop | Audience targeting/activation | Downstream—delivers the content Solstice creates |
| Veeva Crossix | Campaign measurement | Measures performance of content |
| DeepIntent/PulsePoint | HCP programmatic DSPs | Distribution channels |
| Veeva PromoMats | DAM/MLR workflows | Platform Solstice integrates into |

---

## Strategic Implications for Solstice

### **Tailwinds from Real Chemistry/Swoop Dynamics**

1. **Agency Margin Pressure Is Real**
   - The Swoop spin-off confirms that PE (New Mountain) sees services businesses as lower-growth/lower-multiple than tech
   - Real Chemistry without Swoop is a "good but not great" services business—exactly the kind of incumbent Solstice can pick off

2. **"Tech-Enabled Services" Is the Transition State**
   - Pharma is moving from pure agency relationships → tech-enabled internal teams
   - Solstice sits at the right point in this transition: Just as Canva gives anyone the ability to be a designer and Cursor gives anyone the ability to design software—we'd like to give biopharma marketers the ability to create their own content themselves without relying on external agencies.

3. **Veeva Ecosystem Is Still Open**
   - Veeva's AI moves are focused on *workflow optimization*, not *content generation*
   - Marketing, brand, and commercial operations teams work with many external agencies, spanning content creation to rights management. Veeva's Content Partner Program exists explicitly to support third-party content tools
   - Solstice should consider becoming a Veeva Content Partner to lock in distribution

### **Risks to Monitor**

1. **Veeva Expands into Content Generation**
   - Low probability near-term (not their core competency), but they have the distribution to crush point solutions if they decide to
   - Mitigation: Move fast, build customer relationships, create switching costs

2. **Real Chemistry / Big Agencies Build AI Tools**
   - "There's no real way RC can recreate their business"—bold claim in your internal docs, but agencies are definitely trying
   - Watch for: Agency acquisitions of AI content startups, internal AI lab announcements

3. **Pharma Budget Cuts Hit "New Vendor" Spend First**
   - If macro tightens, established agency relationships may be "safer" than new tech vendors
   - Mitigation: Land-and-expand strategy, prove ROI quickly, target innovation-forward clients (Sanofi, Takeda Oncology already in pipeline)

---

## The "So What" for Your Board Conversations

**Narrative for Solstice's Next Raise:**

> "Real Chemistry just got carved up because PE recognized that services businesses can't keep pace with tech-enabled disruption. Veeva is adding AI to their workflow tools, but they're not touching content creation—that's still owned by expensive agencies charging $50K for a slide deck. We're the Canva for life sciences content: same Veeva integration, 100x faster, fraction of the cost. Our pipeline includes Sanofi, Takeda Oncology, and AstraZeneca—proof that enterprise pharma is ready to move."

**Key Proof Points to Track:**
- Win rate against agency incumbents (Real Chemistry, Klick, etc.)
- Veeva integration depth and potential Content Partner status
- ACV expansion within accounts (Phathom → Ipsen → Sanofi trajectory)
- Time-to-content metrics vs. agency benchmarks (the "3 months → minutes" claim)

---

Want me to dig deeper on any specific competitive angle, help refine the fundraise positioning, or map out potential acquirers for Solstice down the road?



## Response:
12/20/2025, 12:07:14 PM

````plaintext
Thought process: Weighed strategic expansion feasibility across data, capabilities, and competitive dynamics.

The user is asking whether Solstice could expand into Swoop-like offerings (audience targeting, activation, omnichannel marketing tech) over time. This is a strategic question about horizontal expansion.

Let me think through this systematically:

1. What Solstice does today: AI-powered content creation for life sciences, integrating with Veeva for MLR compliance
2. What Swoop does: Audience targeting/segmentation using claims data, predictive AI for patient/HCP identification, omnichannel activation

The question is whether it makes sense for Solstice to move "downstream" from content creation into targeting/activation.

Key considerations:
- Data assets required
- Technical capabilities
- Go-to-market motion
- Customer relationships
- Competitive dynamics
- Capital requirements

Let me think through the bull and bear cases.
````

Great strategic question. Let me break this down systematically.

---

## The Core Question: Can Solstice Move Downstream?

**Current State:**
```
[Content Creation] → [Targeting/Segmentation] → [Activation/Delivery] → [Measurement]
     SOLSTICE              SWOOP                    SWOOP/DSPs           CROSSIX
     
     "What to say"         "Who to reach"           "How to reach"       "Did it work"
```

You're asking: can Solstice expand rightward into Swoop's territory?

---

## Why It Could Make Sense (The Bull Case)

### **1. Customer Overlap Is High**

Solstice and Swoop sell to the same buyers: brand marketing teams at pharma companies. The person deciding on content creation is often the same person (or adjacent team) deciding on audience targeting.

From your docs, Solstice is already talking to Sanofi, Takeda Oncology, AstraZeneca—these are exactly the companies spending with Swoop.

**Strategic logic:** If you own the content, you have a natural right to help distribute it. "We made your assets—now let us help you target the right HCPs/patients with them."

### **2. Content + Targeting = Closed-Loop Personalization**

The holy grail in pharma marketing is **modular content + dynamic targeting**: create content variants, then serve the right variant to the right HCP based on their profile/behavior.

Right now this requires:
- Agency (Real Chemistry) to create modular content
- Swoop/DSP to target audiences
- Veeva to manage the assets
- Crossix to measure

That's 4+ vendors stitched together. A platform that handles content creation + targeting could offer a tighter feedback loop:

> "Your diabetes slide deck performs 2x better with endocrinologists who've prescribed GLP-1s before—here's a variant optimized for that segment."

This is a wedge Swoop can't easily replicate (they don't create content) and agencies can't easily replicate (they don't have targeting tech).

### **3. Swoop's Data Moat Is Narrower Than It Appears**

Swoop's core asset is:
- 300M+ de-identified patient records
- Claims/Rx data for targeting
- HIPAA-certified infrastructure

But they **license** much of this data from the same sources available to others (IQVIA, claims clearinghouses, EHR aggregators). The proprietary layer is their ML models for segmentation and their activation partnerships.

**If Solstice wanted to play in targeting:**
- They could partner with data providers (IQVIA, Komodo Health, Datavant) rather than build from scratch
- The ML/AI capability is arguably Solstice's strength already
- The harder part is the DSP integrations and activation infrastructure—but that's buildable

### **4. MyHealthTeam Acquisition Shows the Playbook**

Swoop just acquired MyHealthTeam to own **first-party patient communities**—opted-in patients who engage directly.

Solstice could mirror this by acquiring/building **HCP engagement tools**:
- Content portals where HCPs access brand materials
- Rep-triggered content delivery
- On-demand content requests from physicians

This would give Solstice first-party HCP engagement data → targeting signal without needing claims data.

---

## Why It Might NOT Make Sense (The Bear Case)

### **1. Completely Different Data Infrastructure**

Solstice's current tech stack is built around:
- Document/content generation
- Veeva integration (DAM/MLR)
- Compliance rule engines

Swoop's tech stack is built around:
- Claims data ingestion and de-identification
- Patient/HCP identity graphs
- Real-time bidding and programmatic activation
- Privacy-safe matching (clean rooms, tokenization)

These are fundamentally different systems. Building Swoop-like capabilities would require:
- HIPAA-certified data infrastructure (not trivial)
- Relationships with claims data providers
- Integrations with DSPs, publishers, CTV platforms
- Privacy/compliance expertise in a different domain

**Capital requirement:** Swoop has raised significant capital and was built/acquired for this over 10+ years. Replicating it is a multi-year, multi-tens-of-millions endeavor.

### **2. Different Buyer, Different Sale**

While brand marketing teams touch both content and media, the actual buyers are often different:

| Function | Content Creation | Media/Targeting |
|----------|------------------|-----------------|
| Primary Buyer | Brand Marketing, Med Affairs | Omnichannel/Digital Marketing, Media |
| Budget Owner | Marketing Ops, Agency Fees | Media Spend, Digital |
| Decision Criteria | Speed, compliance, quality | Reach, precision, ROI |
| Procurement | Services/SaaS | Media + Tech |

Selling content software ≠ selling adtech. The competitive dynamics, pricing models, and proof points are different.

### **3. You'd Be Competing with Your Distribution Partners**

Swoop partners with agencies (Ogilvy Health, FCBHealth, Klick) who are Solstice's *competitors* on content but potential *partners* on activation.

If Solstice moves into targeting:
- Swoop has less reason to play nice
- Agencies might view Solstice as a full-stack threat and push back
- You're now fighting on two fronts instead of one

**Strategic risk:** Trying to be everything to everyone often means being best at nothing.

### **4. Veeva Is the More Natural Expansion Path**

Rather than moving into Swoop's territory, Solstice could expand *deeper* into the Veeva ecosystem:

- **MedComms content** (not just promotional—scientific publications, MSL materials)
- **Regulatory submissions** (eCTD packages, FDA briefing docs)
- **Global adaptation** (localization, country-specific compliance)
- **Claims management** (the reference/annotation layer Veeva already does, but could be AI-enhanced)

This leverages Solstice's existing strengths (content + compliance + Veeva integration) rather than building new muscles.

---

## The Hybrid Play: "Targeting-Informed Content"

The smartest move might be **not** to build Swoop, but to **integrate with** targeting data to make content smarter.

### **What This Looks Like:**

1. **Ingest targeting signals** (from Swoop, Crossix, or first-party data)
2. **Generate content variants** optimized for different segments
3. **Feed back into activation** with content recommendations

**Example workflow:**
> Swoop tells you: "Segment A is high-value, early-career oncologists who respond to clinical data. Segment B is late-career oncologists who respond to peer endorsements."
>
> Solstice generates: Two versions of the same core message, one data-heavy, one testimonial-focused.
>
> Swoop activates: Serves the right version to the right HCP.

This is a **partnership model**, not a replacement model. Solstice becomes the "content brain" that targeting platforms plug into.

### **Why This Makes Sense:**

- Plays to Solstice's strength (AI-powered content generation)
- Doesn't require building HIPAA-certified claims infrastructure
- Creates value for Swoop (they can offer smarter content delivery)
- Positions Solstice as the "intelligence layer" across the stack

---

## Framework: When Does Horizontal Expansion Make Sense?

| Factor | Expand into Swoop Territory? |
|--------|------------------------------|
| Customer overlap | ✅ Yes—same pharma brand teams |
| Technical adjacency | ❌ No—different data/infra stack |
| GTM leverage | ⚠️ Partial—different buyers within same org |
| Capital efficiency | ❌ No—expensive to build from scratch |
| Competitive response | ❌ Risky—creates enemies on multiple fronts |
| Strategic coherence | ⚠️ Questionable—dilutes "content" positioning |

**My take:** Full expansion into Swoop-like offerings is a **5-year, $50M+ bet** that distracts from winning the content layer. The smarter play is:

1. **Win content creation first** (displace agencies, become default for pharma brand teams)
2. **Build integrations with targeting platforms** (Swoop, Crossix, DSPs) to become "content OS"
3. **Acquire first-party engagement channels** (HCP portals, content hubs) for proprietary signal
4. **Then evaluate** whether to build targeting or let partners do it

---

## What Would Change This Calculus?

Solstice should consider building Swoop-like capabilities if:

1. **Swoop gets acquired by a competitor** (e.g., Veeva buys Swoop)—then integration becomes harder, building becomes necessary

2. **Targeting data becomes commoditized**—if IQVIA/Datavant make claims data cheap and accessible, the barrier to entry drops

3. **A "content + targeting" acquirer emerges**—if the exit thesis requires full-stack omnichannel, you'd need to build or buy

4. **First-party data becomes dominant**—if cookie deprecation and privacy rules kill third-party targeting, owning HCP engagement channels becomes critical

---

## Bottom Line for Solstice

**Short-term (next 12-18 months):** Don't build Swoop. Focus on:
- Winning enterprise pharma accounts (Sanofi, AZ, etc.)
- Deepening Veeva integration
- Expanding content types (MedComms, regulatory, global)

**Medium-term (18-36 months):** Build "targeting-informed content" as a feature, not a product:
- Integrate with Swoop/Crossix APIs to ingest segment data
- Auto-generate content variants for different audiences
- Position as the "personalization layer" agencies can't replicate

**Long-term (3-5 years):** Evaluate build vs. partner based on:
- Market structure (does Swoop get rolled up?)
- Data landscape (does first-party win?)
- Solstice's scale (do you have capital to play?)

---

Want me to map out what a "targeting-informed content" product roadmap might look like, or dig into potential partnership structures with Swoop/Crossix?





---
Powered by [Claude Exporter](https://www.claudexporter.com)